Main Menu

ICCG DEVA

A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients.

Disease site: Breast cancer

Treatment modality: Chemotherapy

Status: Closed

Trial details

The DEVA trial was run by the International Collaborative Cancer Group (ICCG) at Imperial College London in collaboration with ICR-CTSU. 

Chief Investigator: Professor R. C. Coombes, Imperial College London

ICR-CTSU Scientific Lead: Professor Judith Bliss

ISRCTN: 89772270

Sponsor: International Collaborative Cancer Group (ICCG)

Funding:  Pfizer, Sanofi-Aventis

Further information

Further information on the DEVA trial may be found on the following sites:

ICCG homepage

Patient friendly summary of the DEVA trial results at CancerHelp UK

Publications and presentations

Coombes RC, Bliss JM, Espie M, et al. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. J. Clin. Oncol. 2011;29(24):3247-54

Coombes RC, Bliss JM, Espie M, et al. DEVA: Randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node-positive postmenopausal early breast cancer (EBC) patients. J. Clin. Oncol. 2010;28(15_suppl):536

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.